Kfar Shaul Hospital, Jerusalem, Israel
08 March 2013
The aim of the study is to test whether Deep TMS with the H-coil to the right DLPC will alleviate refractory delusions in chronic schizophrenic patients. The pharmacological treatment of schizophrenia and other psychosis has improved markedly over the past 20 years. The second and third generation anti psychotics have improved clinical outcome in a significant proportion of patients. However the number of patients suffering from chronic psychosis remains high, many of them remaining in hospitals for prolonged periods of time. Other patients, although more functional and able to live in the community, continue to experience debilitating delusions and hallucinations. We expect Deep TMS to be effective in reducing the delusional content of the thought in these patients, hopefully for extended periods of time.
Contact: Ben Draiman, benjamin.d@PSJER.HEALTH.GOV.IL
Principal Investigator: Dr. Sergay Raskin